Loading clinical trials...
Loading clinical trials...
Safety, Tolerability, and Patient Satisfaction of 16.5% Subcutaneous Immunoglobulin (Cutaquig®) Treatment by Rapid Push in Patients With Primary or Secondary Immunodeficiency (PID or SID)
Conditions
Interventions
Cutaquig®
Locations
1
Canada
University of Alberta
Edmonton, Alberta, Canada
Start Date
April 1, 2023
Primary Completion Date
September 1, 2025
Completion Date
September 1, 2025
Last Updated
January 28, 2025
NCT04232085
NCT03266653
NCT03266627
NCT04197596
NCT02888535
NCT03369301
Lead Sponsor
University of Alberta
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions